Study of a new pill for pulmonary hypertension
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pulmonary hypertension (Group 1 or Group 3) from a right heart catheterization.
- You must have symptoms like shortness of breath or fatigue (WHO Functional Class II or III).
- You must be on stable medications for your condition.
- You must be able to walk between 100 and 550 meters in 6 minutes.
- You must be able to swallow tablets.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.